Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer

Annels, Nicola; Mansfield, David; Arif, Mehreen; Ballesteros‐Merino, Carmen; R. Simpson, Guy; Denyer, Mick; Sandhu, Sarbjinder; Melcher, Alan; J. Harrington, Kevin; Davies, B.; G. Au, Gough; Grose, Mark; Bagwan, Izhar; A. Fox, Bernard; G. Vile, Richard; Mostafid, Hugh; R. Shafren, Darren; Pandha, Hardev

doi:10.1158/1078-0432.ccr-18-4022

Public

Phase I Trial of an ICAM-1-Targeted Immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against Non Muscle-Invasive Bladder Cancer

Published in Clinical Cancer Research • Jul 5, 2019

Authors:

Nicola Annels

David Mansfield

Mehreen Arif

Abstract

PURPOSE: -muscle-invasive bladder cancer (NMIBC)] study evaluated a novel ICAM-1-targeted immunotherapeutic-coxsackievirus A21 as a novel oncolytic agent against bladder cancer. PATIENTS AND METHODS: Fifteen patients enrolled in this "window of opportunity" phase I study, exposing primary bladder ca...

Subject

Oncolytic virus

Medicine

Cancer

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!